AOD9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-23. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
=== Scaffolding === In 2013, using a 3D scaffolding of Matrigel in various configurations, substantial pancreatic organoids was produced in vitro. Clusters of small numbers of cells proliferated into 40,000 cells within one week. The clusters transform into cells that make either digestive enzymes or hormones like insulin, self-organizing into branched pancreatic organoids that resemble the pancreas. The cells are sensitive to the environment, such as gel stiffness and contact with other cells. Individual cells do not thrive; a minimum of four proximate cells was required for subsequent organoid development. Modifications to the medium composition produced either hollow spheres mainly composed of pancreatic progenitors, or complex organoids that spontaneously undergo pancreatic morphogenesis and differentiation. Maintenance and expansion of pancreatic progenitors require active Notch and FGF signaling, recapitulating in vivo niche signaling interactions. The organoids were seen as potentially offering mini-organs for drug testing and for spare insulin-producing cells. Aside from Matrigel 3D scaffolds, other collagen gel systems have been developed. Collagen/hyaluronic acid scaffolds have been used for modeling the mammary gland In Vitro while co-coculturing epithelial and adipocyte cells. The HyStem kit is another 3D platform containing ECM components and hyaluronic acid that has been used for cancer research. Additionally, hydrogel constituents can be chemically modified to assist in crosslinking and enhance their mechanical properties.
=== In maquettes and artificial proteins === It is possible to incorporate Fe–S clusters into maquettes (smaller minimal functional proteins designed from biological proteins) and artificial proteins, often abbreviated to MAPs. The first examples of Fe–S MAPs emerged in the early 1970s, as a means to mimic naturally occurring iron-containing proteins like rubredoxins. These contained [Fe(S-Cys)4] motifs. Further research into [4Fe–4S] MAPs has led to the development of ambidoxins: de novo maquettes that consist of 12 residues with the sequence X-Cys-X2-Cys-X2-Cys-X2-Cys-X (X = Arg, Lys), which can successfully perform hundreds of redox cycles. However, Fe–S MAPs are limited by their lower solubility and exposed Fe–S cluster core that is susceptible to degradation by solvents.
=== Legality of South West Africa, 1946–1960 === After World War II, Jan Smuts headed the South African delegation to the United Nations Conference on International Organization. As a result of this conference, the League of Nations was formally superseded by the United Nations (UN) and former League mandates by a trusteeship system. Article 77 of the United Nations Charter stated that UN trusteeship "shall apply...to territories now held under mandate"; furthermore, it would "be a matter of subsequent agreement as to which territories in the foregoing territories will be brought under the trusteeship system and under what terms". Smuts was suspicious of the proposed trusteeship, largely because of the vague terminology in Article 77. Heaton Nicholls, the South African high commissioner in the United Kingdom and a member of the Smuts delegation to the UN, addressed the newly formed UN General Assembly on 17 January 1946. Nicholls stated that the legal uncertainty of South West Africa's situation was retarding development and discouraging foreign investment; however, self-determination for the time being was impossible since the territory was too undeveloped and underpopulated to function as a strong independent state. In the second part of the first session of the General Assembly, the floor was handed to Smuts, who declared that the mandate was essentially a part of the South African territory and people.
=== 1990s === 1990: Antonia Novello became the first woman, first person of color, and first Hispanic to serve as Surgeon General of the United States. 1991: Doris Malkin Curtis became the first woman president of the Geological Society of America. 1992: Edith M. Flanigen became the first woman awarded the Perkin Medal (widely considered the highest honor in American industrial chemistry) for her outstanding achievements in applied chemistry. The medal especially recognized her syntheses of aluminophosphate and silicoaluminophosphate molecular sieves as new classes of materials. 1992: Mae Jemison becomes the first Black woman to travel into space when she served as a mission specialist aboard the Space Shuttle Endeavour. 1993: Ellen Ochoa became the first Hispanic woman to go to space when she served aboard the Space Shuttle Discovery. 1998: Nurse Fannie Gaston-Johansson became the first African-American woman tenured full professor at Johns Hopkins University. 1998: Rita R. Colwell became the first female director of the National Science Foundation.
Side effects have been mostly mild to moderate and manageable, with no significant liver, eye, or kidney toxicity reported. The ATAC approach is also showing potential in solid tumors. TROP2-targeted conjugates have completely eradicated tumors in preclinical models of pancreatic cancer and triple-negative breast cancer, outperforming the approved drug sacituzumab govitecan. In January 2026, Takeda began a Phase I/II clinical trial of an ATAC candidate for solid tumors. These advances have been reviewed in a 2026 editorial by Italian amanitologist Danny LeVan-Cicchetti, demonstrating how α-amanitin can overcome drug resistance and attack the hidden roots of cancer, offering new promising hope in precision oncology as of May 2026.
Sources: en.wikipedia.org
== Effects on global climate == In climate change science, ENSO is known as one of the internal climate variability phenomena. The other two main ones are Pacific decadal oscillation and Atlantic multidecadal oscillation. La Niña impacts the global climate and disrupts normal weather patterns, which can lead to intense storms in some places and droughts in others. El Niño events cause short-term (approximately 1 year in length) spikes in global average surface temperature while La Niña events cause short term cooling. Therefore, the relative frequency of El Niño compared to La Niña events can affect global temperature trends on decadal timescales.
Ansuvimab, sold under the brand name Ebanga, is a monoclonal antibody medication used for the treatment of Ebolavirus (Zaire ebolavirus) infection. The most common symptoms include fever, tachycardia (fast heart rate), diarrhea, vomiting, hypotension (low blood pressure), tachypnea (fast breathing) and chills; however, these are also common symptoms of Ebolavirus infection. Ansuvimab was approved for medical use in the United States in December 2020. It is on the World Health Organization's List of Essential Medicines. Ansuvimab is composed of a single monoclonal antibody (mAb) and was initially isolated from immortalized B-cells that were obtained from a survivor of the 1995 outbreak of Ebola virus disease in Kikwit, Democratic Republic of the Congo. In work supported by the United States National Institutes of Health and the Defense Advanced Projects Agency, the heavy and light chain sequences of ansuvimab mAb were cloned into Chinese hamster ovary cell lines and initial production runs were produced by Cook Phamica d.b.a. Catalent under contract with Medimmune.
Research has been ongoing since the 1960s to determine the proportion of 14C in the atmosphere over the past 50,000 years. The resulting data, in the form of a calibration curve, is now used to convert a given measurement of radiocarbon in a sample into an estimate of the sample's calendar age. Other corrections must be made to account for the proportion of 14C in different types of organisms (fractionation), and the varying levels of 14C throughout the biosphere (reservoir effects). Additional complications come from the burning of fossil fuels, such as coal and oil, and from the above-ground nuclear tests done in the 1950s and 1960s. Because the time it takes to convert biological materials to fossil fuels is substantially longer than the time it takes for their 14C to decay below detectable levels, fossil fuels contain almost no 14C. As a result, beginning in the late 19th century, there was a noticeable drop in the proportion of 14C as the carbon dioxide generated from burning fossil fuels began to accumulate in the atmosphere. Conversely, nuclear testing increased the amount of 14C in the atmosphere, which reached a maximum in about 1965 of almost double the amount present in the atmosphere prior to nuclear testing. Measurement of radiocarbon was originally done by beta-counting devices, which counted the amount of beta radiation emitted by decaying 14C atoms in a sample.
== Mechanism of action == Exenatide binds to the intact human glucagon-like peptide-1 receptor (GLP-1R) in a similar way to the human peptide glucagon-like peptide-1 (GLP-1); exenatide bears a 50% amino acid homology to GLP-1 and it has a longer half-life in vivo. Exenatide is believed to facilitate glucose control in at least five ways:
Sources: en.wikipedia.org
The proteome can be used in order to comparatively analyze different cancer cell lines. Proteomic studies have been used in order to identify the likelihood of metastasis in bladder cancer cell lines KK47 and YTS1 and were found to have 36 unregulated and 74 down regulated proteins. The differences in protein expression can help identify novel cancer signaling mechanisms. Biomarkers of cancer have been found by mass spectrometry based proteomic analyses. The use of proteomics or the study of the proteome is a step forward in personalized medicine to tailor drug cocktails to the patient's specific proteomic and genomic profile. The analysis of ovarian cancer cell lines showed that putative biomarkers for ovarian cancer include "α-enolase (ENOA), elongation factor Tu, mitochondrial (EFTU), glyceraldehyde-3-phosphate dehydrogenase (G3P), stress-70 protein, mitochondrial (GRP75), apolipoprotein A-1 (APOA1), peroxiredoxin (PRDX2) and annexin A (ANXA)". Comparative proteomic analyses of 11 cell lines demonstrated the similarity between the metabolic processes of each cell line; 11,731 proteins were completely identified from this study. Housekeeping proteins tend to show greater variability between cell lines. Resistance to certain cancer drugs is still not well understood. Proteomic analysis has been used in order to identify proteins that may have anti-cancer drug properties, specifically for the colon cancer drug irinotecan. Studies of adenocarcinoma cell line LoVo demonstrated that 8 proteins were unregulated and 7 proteins were down-regulated.
Metabolites produced from vitamin D2 tend to bind less well to the vitamin D-binding protein. Vitamin D3 can alternatively be hydroxylated to calcifediol by sterol 27-hydroxylase, an enzyme coded for by gene CYP27A1, but vitamin D2 cannot. Ergocalciferol can be directly hydroxylated at position 24 by the enzyme coded for by CYP27A1. This hydroxylation also leads to a greater degree of inactivation: the activity of calcitriol decreases to 60% of original after 24-hydroxylation, whereas ercalcitriol undergoes a 10-fold decrease in activity on conversion to ercalcitetrol.
=== Video games === The Persona series of games is heavily based on Jung's theories, representing the shadow, the persona, and archetype. The Nights into Dreams series of games is heavily based on Jung's theories. Jungian concepts are present in the Xeno series, including Xenogears; its reimagination as the Xenosaga trilogy; and a graphic novel, Perfect Works, published by the game's creator. The game Control is heavily influenced by Carl Jung's ideas, particularly synchronicity and shadow selves. Alan Wake takes inspiration from Carl Jung's ideas of archetype and individuation.
== History == Mazagran, a cold, sweetened coffee beverage that originated in Algeria around 1840, has been described by locals as "the original iced coffee". It was prepared with coffee syrup and cold water. Frozen coffee beverages, similar to slush, are documented in the 19th century. The Italian granita al caffè is a similar beverage. "Iced coffee"—coffee that has been brewed and then chilled with ice—appeared in menus and recipes in the late 19th century. Iced coffee was popularized by a marketing campaign of the Joint Coffee Trade Publicity Committee of the United States in 1920. Much later, it was marketed by chain outlets, including Burger King, Dunkin' Donuts and Starbucks.
=== Molded graphene === In 2015, researchers from the University of Illinois at Urbana–Champaign (UIUC) developed a new approach for forming 3D shapes from flat, 2D sheets of graphene. A film of graphene that had been soaked in solvent to make it swell and become malleable was overlaid on an underlying substrate "former". The solvent evaporated over time, leaving behind a layer of graphene that had taken on the shape of the underlying structure. In this way, they were able to produce a range of relatively intricate micro-structured shapes. Features vary from 3.5 to 50 μm. Pure graphene and gold-decorated graphene were each successfully integrated with the substrate.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.